Ascendis Pharma (ASND)
US Market

Ascendis Pharma (ASND) Financial Statements


Ascendis Pharma Financial Overview

Ascendis Pharma's market cap is currently ―. The company's EPS TTM is $-9.637; its P/E ratio is -14.08; Ascendis Pharma is scheduled to report earnings on August 29, 2024, and the estimated EPS forecast is $-1.49. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue--€ 15.29M€ 6.16M€ 6.83M
Gross Profit--€ 13.60M€ 5.07M€ 2.58M
EBIT--€ -127.88M€ -71.93M€ -119.86M
EBITDA--€ -123.36M€ -67.54M€ -115.44M
Net Income Common Stockholders--€ -168.96M€ -81.32M€ -125.50M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments€ 399.44M€ 22.93M€ 919.81M€ 955.15M€ 978.70M
Total Assets€ 825.59M€ 1.09B€ 1.27B€ 1.33B€ 1.38B
Total Debt€ 644.26M€ 482.96M€ 553.24M€ 512.21M€ 473.66M
Net Debt€ 244.83M€ 460.02M€ -366.57M€ -442.94M€ -505.04M
Total Liabilities€ 971.28M€ 826.39M€ 821.87M€ 718.99M€ 704.43M
Stockholders Equity€ -145.70M€ 0.00€ 451.55M€ 607.84M€ 672.82M
Cash Flow-
Free Cash Flow--€ -102.00M€ -128.12M€ -134.61M
Operating Cash Flow--€ -98.83M€ -124.39M€ -130.79M
Investing Cash Flow--€ 14.10M€ 9.89M€ 38.54M
Financing Cash Flow--€ -76.00K€ -2.23M€ 397.74M
Currency in EUR

Ascendis Pharma Earnings and Revenue History

Ascendis Pharma Debt to Assets

Ascendis Pharma Cash Flow

Ascendis Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis